Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Core Insights - Absci Corporation is a data-first generative AI drug creation company that will participate in the Guggenheim Securities SMID Cap Biotech Conference in New York on February 5, 2025 [1][2]. Company Overview - Absci combines AI with scalable wet lab technologies to enhance the development of biologics, aiming to accelerate the time to clinic and improve the probability of success by optimizing multiple drug characteristics simultaneously [3]. - The company's Integrated Drug Creation™ platform allows for the screening of billions of cells weekly, enabling a transition from AI-designed candidates to wet lab-validated candidates in as little as six weeks [3]. - Absci's headquarters is located in Vancouver, WA, with additional facilities including an AI Research Lab in New York City and an Innovation Center in Zug, Switzerland [3].